<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01846507</url>
  </required_header>
  <id_info>
    <org_study_id>NCH12-00822</org_study_id>
    <nct_id>NCT01846507</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding</brief_title>
  <official_title>Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to learn more about a drug called Tranexamic acid (TA), otherwise known as
      Lysteda, and whether or not this drug can decrease menstrual blood loss in young women and
      lead to an increase in the quality of life.

      Menorrhagia in young women with bleeding disorders is typically treated with a combination of
      treatments including hormonal contraceptives. However, there are barriers to hormonal
      contraception use in younger adolescents.

      Tranexamic acid is taken orally during the first 5 days of menstrual bleeding.

      The purposes of this study include:

      To test the safety and efficacy of Lysteda in adolescent females. To learn how well Lysteda
      works in decreasing menstrual blood loss. To see if parents and children participating in
      this study think the drug is improving their quality of life.

      Lysteda has been approved by the Food and Drug Administration for use in patients &gt; than 18
      years of age but not for younger patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center (5 sites) open-label, single-arm, efficacy study of Lysteda in the
      treatment of adolescent females (10-19 years of age) with heavy menstrual bleeding (HMB).
      Each subject will receive oral Lysteda 1.3 grams three times daily during the first five days
      of menses. Subjects will be monitored over the course of four menstrual cycles (1
      pre-treatment cycle and 3 treatment cycles). During all cycles, assessments of menstrual
      bleeding will be performed using the Menorrhagia Impact Questionnaire (MIQ) and Pictorial
      Blood Assessment Chart (PBAC).

      The study will begin as a currently funded pilot study to assess the efficacy of Lysteda in
      32 patients followed to study completion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline Menses for Participant Perceived Blood Loss</measure>
    <time_frame>Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid</time_frame>
    <description>Menorrhagia Impact Questionnaire (MIQ): Question 1 - participant perceived blood loss during most recent menses. Scale ranges from a score of 1 to 4 (with 1 being light blood loss and 4 being very heavy blood loss). Lower values indicate a better outcome (less blood loss during menses). Unit of measure is scores on a scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Menses for Participant Perceived Limitation of School Attendance</measure>
    <time_frame>Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid</time_frame>
    <description>Menorrhagia Impact Questionnaire (MIQ): Question 2 - participant perceived limitation of school attendance during most recent menses. Scale ranges from a score of 1 to 5 (with 1 being school attendance not at all limited and 5 being school attendance limited extremely). Lower values indicate a better outcome (less limitation of school attendance). Unit of measure is scores on a scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Menses for Participant Perceived Limitation in Physical Activities</measure>
    <time_frame>Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid</time_frame>
    <description>Menorrhagia Impact Questionnaire (MIQ): Question 3 - participant perceived limitation in physical activities during most recent menses. Scale ranges from a score of 1 to 5 (with 1 being physical activities not at all limited and 5 being physical activities extremely limited). Lower values indicate a better outcome (less limitation of physical activities). Unit of measure is scores on a scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Menses for Participant Perceived Limitation of Social or Leisure Activities</measure>
    <time_frame>Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid</time_frame>
    <description>Menorrhagia Impact Questionnaire (MIQ): Question 4 - participant perceived limitation of social or leisure during most recent menses. Scale ranges from a score of 1 to 5 (with 1 being social or leisure activities not at all limited and 5 being social or leisure activities limited extremely). Lower values indicate a better outcome (less limitation of social or leisure activities). Unit of measure is scores on a scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Menses for Menstrual Blood Loss as Measured by Pictorial Blood Assessment Chart (PBAC) Scores</measure>
    <time_frame>Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid</time_frame>
    <description>Pictorial Blood Assessment Chart (PBAC) scores - participant assessment of menstrual blood loss during menses using a pictorial chart to score menstrual blood loss. Pictorial scores range from 1 point for mild soaking of a pad/tampon, 5 points for moderate soaking of a pad/tampon, 10 points for severe soaking of a pad/tampon, and 5 points for each episode of flooding and for each blood clot larger than a quarter in size. Lower values indicate a better outcome (less blood loss). Unit of measure is a total computed score (all points during the menses from the pictorial chart added together).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Menses for Hemoglobin Lab Value</measure>
    <time_frame>Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid</time_frame>
    <description>Hemoglobin lab value normal range is 12 g/dL to 16 g/dL. Values in the range of 12 g/dL to 16 g/dL would be considered normal Hemoglobin values. A score lower than the normal range (below 12 g/dL) would indicate a worse outcome. Unit of measure is g/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Menses for Ferritin Lab Value</measure>
    <time_frame>Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid</time_frame>
    <description>Ferritin lab value normal range is 7 ng/mL to 142 ng/mL. Values in the range of 7ng/mL to 142 ng/mL would be considered normal Ferritin values. A score lower than the normal range (below 7 ng/mL) would indicate a worse outcome. Unit of measure is ng/mL.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Heavy Menstrual Bleeding</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will complete a baseline menses (no treatment) followed by 3 menses using tranexamic acid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Subjects will be instructed to take 2 tablets (1300) mg of Lysteda three times daily (3900 mg/daily) for five days during monthly menstruation.</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <other_name>Lysteda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Menstruating females 10-19 years of age

          2. Non-smoker

          3. Physician and patient have agreed to initiate Lysteda

          4. Diagnosis of HMB based on the medical judgment of the principal or site investigator

          5. Subjects must report menstrual periods occurring within 21-60 days from the start of
             one period to the start of the next menstrual period

          6. Negative pregnancy test

          7. Informed consent obtained and signed

          8. Informed assent obtained and signed

          9. Understanding of study procedures

         10. Ability to comply with study procedures for the entire length of the study

         11. Subjects should be either sexually inactive (abstinent) or agree to use a barrier
             method with spermicide in the event of sexual activity throughout the study period

        Exclusion Criteria:

          1. Active thromboembolic disease, history of thromboembolic disease (including retinal
             vein or artery occlusion), known inherited thrombophilia, or family history of
             thrombosis in a first degree relative

          2. Subject has a severe medical or psychiatric illness that, in the opinion of the
             Investigator, would affect subject safety or compliance

          3. Clinical evidence of severe bleeding disorder. Patients with mild bleeding disorders
             such as type 1 von Willebrand disease, mild platelet function defects such as platelet
             storage pool or release defects, and patients with bleeding due to Ehlers Danlos
             syndrome WILL be eligible to participate in the study.

          4. Pregnancy within the past 6 months and/or breast-feeding

          5. Use of hormonal contraception (estrogen and progestin) within 3 months of study entry,
             or anticipated need to initiate estrogen-containing hormonal contraception during the
             study period

          6. Use of systemic steroids within 1 month of study entry

          7. History of subarachnoid hemorrhage

          8. History of Hepatitis B, C, or HIV

          9. Baseline creatinine &gt;20% above the upper limit of normal for age

         10. Severe anemia (hemoglobin &lt;8 g/dL)

         11. Systolic blood pressure &lt;85 or diastolic blood pressure &lt;55

         12. Heart rate &lt;50 at time of screening

         13. Use of intranasal DDAVP during menses will be permitted, but only if the patient has a
             history of using DDAVP consistently for â‰¥3 menstrual cycles prior to study enrollment,
             so that change in menstrual blood loss due to addition of Lysteda can be assessed. Use
             of one-time DDAVP during a DDAVP/Stimate challenge is also permitted during the study
             period, as is use of DDAVP in the event of severe epistaxis, trauma, or surgical
             procedures during the study period.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah O'Brien, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Riley Hospital for Children at IU Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies &amp; Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 1, 2013</study_first_submitted>
  <study_first_submitted_qc>May 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2013</study_first_posted>
  <results_first_submitted>March 7, 2018</results_first_submitted>
  <results_first_submitted_qc>June 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2018</results_first_posted>
  <last_update_submitted>September 28, 2018</last_update_submitted>
  <last_update_submitted_qc>September 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nationwide Children's Hospital</investigator_affiliation>
    <investigator_full_name>Sarah O'Brien</investigator_full_name>
    <investigator_title>Director of Experimental Therapeutics</investigator_title>
  </responsible_party>
  <keyword>Heavy Menstrual Bleeding</keyword>
  <keyword>HMB</keyword>
  <keyword>Lysteda</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menorrhagia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Baseline menses (no treatment) followed by 3 menses using tranexamic acid.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tranexamic Acid</title>
          <description>Adolescent girls aged 10-19 years with heavy menstrual bleeding</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing data</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tranexamic Acid</title>
          <description>Tranexamic Acid: Subjects will be instructed to take 2 tablets (1300) mg of Lysteda three times daily (3900 mg/daily) for five days during monthly menstruation.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.7" lower_limit="11" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Menses for Participant Perceived Blood Loss</title>
        <description>Menorrhagia Impact Questionnaire (MIQ): Question 1 - participant perceived blood loss during most recent menses. Scale ranges from a score of 1 to 4 (with 1 being light blood loss and 4 being very heavy blood loss). Lower values indicate a better outcome (less blood loss during menses). Unit of measure is scores on a scale.</description>
        <time_frame>Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Menses</title>
            <description>Adolescent girls aged 10-19 with heavy menstrual bleeding - Baseline menses with no treatment</description>
          </group>
          <group group_id="O2">
            <title>Treated With Tranexamic Acid During Menses</title>
            <description>Adolescent girls aged 10-19 years with heavy menstrual bleeding - treatment with Tranexamic Acid for 3 menses</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Menses for Participant Perceived Blood Loss</title>
          <description>Menorrhagia Impact Questionnaire (MIQ): Question 1 - participant perceived blood loss during most recent menses. Scale ranges from a score of 1 to 4 (with 1 being light blood loss and 4 being very heavy blood loss). Lower values indicate a better outcome (less blood loss during menses). Unit of measure is scores on a scale.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Menses for Participant Perceived Limitation of School Attendance</title>
        <description>Menorrhagia Impact Questionnaire (MIQ): Question 2 - participant perceived limitation of school attendance during most recent menses. Scale ranges from a score of 1 to 5 (with 1 being school attendance not at all limited and 5 being school attendance limited extremely). Lower values indicate a better outcome (less limitation of school attendance). Unit of measure is scores on a scale.</description>
        <time_frame>Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Menses</title>
            <description>Adolescent girls aged 10-19 years with heavy menstrual bleeding - Baseline menses with no treatment</description>
          </group>
          <group group_id="O2">
            <title>Treated With Tranexamic Acid During Menses</title>
            <description>Adolescent girls aged 10-19 years with heavy menstrual bleeding - treatment with Tranexamic Acid for 3 menses</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Menses for Participant Perceived Limitation of School Attendance</title>
          <description>Menorrhagia Impact Questionnaire (MIQ): Question 2 - participant perceived limitation of school attendance during most recent menses. Scale ranges from a score of 1 to 5 (with 1 being school attendance not at all limited and 5 being school attendance limited extremely). Lower values indicate a better outcome (less limitation of school attendance). Unit of measure is scores on a scale.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O2" value="1.27" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Menses for Participant Perceived Limitation in Physical Activities</title>
        <description>Menorrhagia Impact Questionnaire (MIQ): Question 3 - participant perceived limitation in physical activities during most recent menses. Scale ranges from a score of 1 to 5 (with 1 being physical activities not at all limited and 5 being physical activities extremely limited). Lower values indicate a better outcome (less limitation of physical activities). Unit of measure is scores on a scale.</description>
        <time_frame>Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Menses</title>
            <description>Adolescent girls aged 10-19 years with heavy menstrual bleeding - Baseline menses with no treatment</description>
          </group>
          <group group_id="O2">
            <title>Treated With Tranexamic Acid During Menses</title>
            <description>Adolescent girls aged 10-19 years with heavy menstrual bleeding - treatment with Tranexamic Acid for 3 menses</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Menses for Participant Perceived Limitation in Physical Activities</title>
          <description>Menorrhagia Impact Questionnaire (MIQ): Question 3 - participant perceived limitation in physical activities during most recent menses. Scale ranges from a score of 1 to 5 (with 1 being physical activities not at all limited and 5 being physical activities extremely limited). Lower values indicate a better outcome (less limitation of physical activities). Unit of measure is scores on a scale.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O2" value="1.40" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Menses for Participant Perceived Limitation of Social or Leisure Activities</title>
        <description>Menorrhagia Impact Questionnaire (MIQ): Question 4 - participant perceived limitation of social or leisure during most recent menses. Scale ranges from a score of 1 to 5 (with 1 being social or leisure activities not at all limited and 5 being social or leisure activities limited extremely). Lower values indicate a better outcome (less limitation of social or leisure activities). Unit of measure is scores on a scale.</description>
        <time_frame>Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Menses</title>
            <description>Adolescent girls aged 10-19 years with heavy menstrual bleeding - Baseline menses with no treatment</description>
          </group>
          <group group_id="O2">
            <title>Treated With Tranexamic Acid During Menses</title>
            <description>Adolescent girls aged 10-19 years with heavy menstrual bleeding - treatment with Tranexamic Acid for 3 menses</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Menses for Participant Perceived Limitation of Social or Leisure Activities</title>
          <description>Menorrhagia Impact Questionnaire (MIQ): Question 4 - participant perceived limitation of social or leisure during most recent menses. Scale ranges from a score of 1 to 5 (with 1 being social or leisure activities not at all limited and 5 being social or leisure activities limited extremely). Lower values indicate a better outcome (less limitation of social or leisure activities). Unit of measure is scores on a scale.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O2" value="1.76" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Menses for Menstrual Blood Loss as Measured by Pictorial Blood Assessment Chart (PBAC) Scores</title>
        <description>Pictorial Blood Assessment Chart (PBAC) scores - participant assessment of menstrual blood loss during menses using a pictorial chart to score menstrual blood loss. Pictorial scores range from 1 point for mild soaking of a pad/tampon, 5 points for moderate soaking of a pad/tampon, 10 points for severe soaking of a pad/tampon, and 5 points for each episode of flooding and for each blood clot larger than a quarter in size. Lower values indicate a better outcome (less blood loss). Unit of measure is a total computed score (all points during the menses from the pictorial chart added together).</description>
        <time_frame>Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Menses</title>
            <description>Adolescent girls aged 10-19 years with heavy menstrual bleeding - Baseline menses with no treatment</description>
          </group>
          <group group_id="O2">
            <title>Treated With Tranexamic Acid During Menses</title>
            <description>Adolescent girls aged 10-19 years with heavy menstrual bleeding - treatment with Tranexamic Acid for 3 menses</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Menses for Menstrual Blood Loss as Measured by Pictorial Blood Assessment Chart (PBAC) Scores</title>
          <description>Pictorial Blood Assessment Chart (PBAC) scores - participant assessment of menstrual blood loss during menses using a pictorial chart to score menstrual blood loss. Pictorial scores range from 1 point for mild soaking of a pad/tampon, 5 points for moderate soaking of a pad/tampon, 10 points for severe soaking of a pad/tampon, and 5 points for each episode of flooding and for each blood clot larger than a quarter in size. Lower values indicate a better outcome (less blood loss). Unit of measure is a total computed score (all points during the menses from the pictorial chart added together).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255.1" lower_limit="62" upper_limit="699"/>
                    <measurement group_id="O2" value="154.6" lower_limit="12" upper_limit="561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Menses for Hemoglobin Lab Value</title>
        <description>Hemoglobin lab value normal range is 12 g/dL to 16 g/dL. Values in the range of 12 g/dL to 16 g/dL would be considered normal Hemoglobin values. A score lower than the normal range (below 12 g/dL) would indicate a worse outcome. Unit of measure is g/dL.</description>
        <time_frame>Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Menses</title>
            <description>Adolescent girls aged 10-19 with heavy menstrual bleeding - Baseline menses with no treatment</description>
          </group>
          <group group_id="O2">
            <title>Treated With Tranexamic Acid During Menses</title>
            <description>Adolescent girls aged 10-19 years with heavy menstrual bleeding - treatment with Tranexamic Acid for 3 menses</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Menses for Hemoglobin Lab Value</title>
          <description>Hemoglobin lab value normal range is 12 g/dL to 16 g/dL. Values in the range of 12 g/dL to 16 g/dL would be considered normal Hemoglobin values. A score lower than the normal range (below 12 g/dL) would indicate a worse outcome. Unit of measure is g/dL.</description>
          <units>gm/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.67" lower_limit="10.4" upper_limit="15.3"/>
                    <measurement group_id="O2" value="12.84" lower_limit="10.6" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Menses for Ferritin Lab Value</title>
        <description>Ferritin lab value normal range is 7 ng/mL to 142 ng/mL. Values in the range of 7ng/mL to 142 ng/mL would be considered normal Ferritin values. A score lower than the normal range (below 7 ng/mL) would indicate a worse outcome. Unit of measure is ng/mL.</description>
        <time_frame>Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Menses</title>
            <description>Adolescent girls aged 10-19 years with heavy menstrual bleeding - Baseline menses with no treatment</description>
          </group>
          <group group_id="O2">
            <title>Treated With Tranexamic Acid During Menses</title>
            <description>Adolescent girls aged 10-19 years with heavy menstrual bleeding - treatment with Tranexamic Acid for 3 menses</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Menses for Ferritin Lab Value</title>
          <description>Ferritin lab value normal range is 7 ng/mL to 142 ng/mL. Values in the range of 7ng/mL to 142 ng/mL would be considered normal Ferritin values. A score lower than the normal range (below 7 ng/mL) would indicate a worse outcome. Unit of measure is ng/mL.</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.94" lower_limit="4" upper_limit="82"/>
                    <measurement group_id="O2" value="26.34" lower_limit="5" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tranexamic Acid</title>
          <description>Adolescent girls aged 10-19 years with heavy menstrual bleeding</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection sypmtoms</sub_title>
                <counts group_id="E1" events="23" subjects_affected="14" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Heavy menses</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size Subjective measurement of menstrual blood loss</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sarah O'Brien, MD</name_or_title>
      <organization>Nationwide Children's Hospital</organization>
      <phone>614-722-3070</phone>
      <email>sarah.obrien@nationwidechildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

